|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12...345678910111213...4647» |
- Enrollment closed: Mealtime Symptoms in Dementia (clinicaltrials.gov) - Oct 7, 2016
P=N/A, N=132, Active, not recruiting, Sponsor: Duke University
Enrolling by invitation --> Active, not recruiting
- Enrollment closed: IU-CHOICE: Indiana University Dementia Screening Trial (clinicaltrials.gov) - Oct 4, 2016
P=N/A, N=4000, Active, not recruiting, Sponsor: Indiana University
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: The Genetic Characterization of Dementia (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=300, Completed, Sponsor: National Institute on Aging (NIA)
Recruiting --> Active, not recruiting Terminated --> Completed
- ||| donepezil / Generic mfg.
Trial completion: A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS) (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=540, Completed, Sponsor: Eisai Korea Inc.
Terminated --> Completed Active, not recruiting --> Completed
- Trial completion: Cognitive Intervention For Delirium in Dementia (clinicaltrials.gov) - Sep 27, 2016
P2, N=283, Completed, Sponsor: Penn State University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=28, Completed, Sponsor: Ohio State University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Trial completion: STARSHINE: Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil (clinicaltrials.gov) - Sep 26, 2016
P3, N=932, Completed, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination, Trial primary completion date: The Genetic Characterization of Dementia (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=300, Terminated, Sponsor: National Institute on Aging (NIA)
Active, not recruiting --> Completed Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016
- | memantine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: AD-IDEA: Alzheimer's Disease - Input of Vitamin D With mEmantine Assay (clinicaltrials.gov) - Sep 22, 2016
P3, N=90, Completed, Sponsor: University Hospital, Angers
Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016 Recruiting --> Completed | N=120 --> 90 | Trial primary completion date: Feb 2013 --> Jan 2016
- Trial completion, Enrollment change, Trial primary completion date: Gait and Alzheimer Interaction Tracking (GAIT) Study (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=912, Completed, Sponsor: University Hospital, Angers
Recruiting --> Completed | N=120 --> 90 | Trial primary completion date: Feb 2013 --> Jan 2016 Recruiting --> Completed | N=600 --> 912 | Trial primary completion date: Nov 2012 --> May 2016
- Enrollment closed, Trial primary completion date: Oral Health Intervention Pilot Study for Individuals With Memory Problems (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: Duke University
Recruiting --> Completed | N=600 --> 912 | Trial primary completion date: Nov 2012 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Feb 2017
- donepezil / Generic mfg.
Trial completion, Enrollment change: Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil (clinicaltrials.gov) - Sep 21, 2016
P4, N=41, Completed, Sponsor: New York State Psychiatric Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Feb 2017 Active, not recruiting --> Completed | N=60 --> 41
- ||| osoresnontrine (BI 409306) / Boehringer Ingelheim
Enrollment change: Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo (clinicaltrials.gov) - Sep 21, 2016
P2, N=150, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=60 --> 41 N=288 --> 150
- isoflurane / Generic mfg.
Enrollment open: Reconstructing Consciousness and Cognition (clinicaltrials.gov) - Sep 21, 2016
P=N/A, N=60, Recruiting, Sponsor: University of Michigan
N=288 --> 150 Active, not recruiting --> Recruiting
- Enrollment change, Trial termination, Trial primary completion date, Surgery: Role of Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery (clinicaltrials.gov) - Sep 16, 2016
P3, N=15, Terminated, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Recruiting N=120 --> 15 | Recruiting --> Terminated | Trial primary completion date: Jun 2010 --> Dec 2010; low enrollment
- haloperidol / Generic mfg.
Trial completion, Surgery: HALPCARD: Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium (clinicaltrials.gov) - Sep 16, 2016
P3, N=25, Completed, Sponsor: McMaster University
N=120 --> 15 | Recruiting --> Terminated | Trial primary completion date: Jun 2010 --> Dec 2010; low enrollment Active, not recruiting --> Completed
- Enrollment closed, Enrollment change, Trial primary completion date: PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers (clinicaltrials.gov) - Sep 15, 2016
P1, N=21, Active, not recruiting, Sponsor: Dean F. Wong, MD, PhD
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=30 --> 21 | Trial primary completion date: Jun 2016 --> Dec 2016
- Trial completion, Trial initiation date, Trial primary completion date: Cerebral Regional Oxygen Saturation and Markers of Brain Damage During Primary Hip Arthroplasty (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=18, Completed, Sponsor: Military Institute of Medicine, Poland
Recruiting --> Active, not recruiting | N=30 --> 21 | Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Completed | Initiation date: Jan 2014 --> Jun 2014 | Trial primary completion date: May 2015 --> Dec 2015
- || landipirdine (SYN120) / Acorda
Trial primary completion date: SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (clinicaltrials.gov) - Sep 13, 2016
P2, N=80, Recruiting, Sponsor: Biotie Therapies Inc.
Recruiting --> Completed | Initiation date: Jan 2014 --> Jun 2014 | Trial primary completion date: May 2015 --> Dec 2015 Trial primary completion date: Dec 2016 --> Dec 2017
- ||| osoresnontrine (BI 409306) / Boehringer Ingelheim
Enrollment change, Trial primary completion date: BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease. (clinicaltrials.gov) - Sep 7, 2016
P2, N=354, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2016 --> Dec 2017 N=293 --> 354 | Trial primary completion date: Apr 2017 --> Sep 2017
- Trial completion, Enrollment change: Music-with-Movement Intervention for People With Early Dementia and Their Families (clinicaltrials.gov) - Sep 6, 2016
P=N/A, N=95, Completed, Sponsor: The Hong Kong Polytechnic University
N=293 --> 354 | Trial primary completion date: Apr 2017 --> Sep 2017 Active, not recruiting --> Completed | N=134 --> 95
- Enrollment change, HEOR: Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids (clinicaltrials.gov) - Aug 30, 2016
P=N/A, N=51, Completed, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed | N=134 --> 95 N=30 --> 51
- Trial completion, Enrollment change: Nicotine Replacement Therapy in the Intensive Care Unit (clinicaltrials.gov) - Aug 29, 2016
P4, N=47, Completed, Sponsor: Gelderse Vallei Hospital
N=30 --> 51 Recruiting --> Completed | N=70 --> 47
- Trial completion, HEOR: Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids (clinicaltrials.gov) - Aug 25, 2016
P=N/A, N=30, Completed, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed | N=70 --> 47 Recruiting --> Completed
- Trial primary completion date: Imaging of Cognition, Learning, and Memory in Aging (clinicaltrials.gov) - Aug 25, 2016
P=N/A, N=550, Recruiting, Sponsor: Yaakov Stern
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- |||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Trial primary completion date: STARSHINE: Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil (clinicaltrials.gov) - Aug 25, 2016
P3, N=932, Active, not recruiting, Sponsor: H. Lundbeck A/S
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Oct 2016 --> Jul 2016
- Trial completion, Metastases: A Pilot Study of an RCT to Improve Infection Management in Advanced Dementia (clinicaltrials.gov) - Aug 23, 2016
P2, N=62, Completed, Sponsor: Hebrew Rehabilitation Center, Boston
Trial primary completion date: Oct 2016 --> Jul 2016 Active, not recruiting --> Completed
- Trial completion: PRAXALIM: Conservation of Praxis in the Food and Alzheimer Disease (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=32, Completed, Sponsor: University Hospital, Limoges
Active, not recruiting --> Completed Recruiting --> Completed
- atorvastatin / Generic mfg.
Trial primary completion date: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Aug 22, 2016
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Oct 2016
- Trial primary completion date: Tau Imaging of Chronic Traumatic Encephalopathy (clinicaltrials.gov) - Aug 17, 2016
P2, N=30, Enrolling by invitation, Sponsor: Marcelo F. Di Carli, MD, FACC
Trial primary completion date: Dec 2015 --> Oct 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- MK-7622 / Merck (MSD)
Phase classification: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Aug 17, 2016
P2a/2b, N=240, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jun 2016 --> Dec 2016 Phase classification: P2a --> P2a/2b
- | S-equol (AUS-131) / Ausio Pharma
Trial completion, Trial primary completion date: S-Equol in Alzheimer's Disease (SEAD) Trial (clinicaltrials.gov) - Aug 16, 2016
P1, N=15, Completed, Sponsor: Russell Swerdlow, MD
Phase classification: P2a --> P2a/2b Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016
- Trial suspension: PET Imaging in MCI Following ADT for PCa (clinicaltrials.gov) - Aug 15, 2016
P=N/A, N=12, Suspended, Sponsor: Imperial College London
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016 Recruiting --> Suspended
- blarcamesine (Anavex 2-73) / Anavex
Phase classification, PK/PD data: Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (clinicaltrials.gov) - Aug 13, 2016
P2a, N=32, Active, not recruiting, Sponsor: Anavex Life Sciences Corp.
Recruiting --> Suspended Phase classification: P2 --> P2a
- Enrollment change, Trial termination, Trial primary completion date: AZAP: Sleep Apnea in Early to Mid-Stage Alzheimer's Disease (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=22, Terminated, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Phase classification: P2 --> P2a N=100 --> 22 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jun 2014; End of the study because of the inclusions were too difficult
- |||| Nine Phase One (mannote sodium) / Shanghai Greenvalley
Trial primary completion date: An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease (clinicaltrials.gov) - Aug 10, 2016
P3, N=788, Recruiting, Sponsor: Shanghai Greenvalley Pharmaceutical Co., Ltd.
N=100 --> 22 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jun 2014; End of the study because of the inclusions were too difficult Trial primary completion date: Dec 2016 --> Sep 2017
- Trial primary completion date: NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment (clinicaltrials.gov) - Aug 9, 2016
P2, N=50, Recruiting, Sponsor: Chang Gung Memorial Hospital
Trial primary completion date: Dec 2016 --> Sep 2017 Trial primary completion date: Jul 2016 --> Dec 2017
- Trial primary completion date: DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia (clinicaltrials.gov) - Aug 9, 2016
P2, N=90, Recruiting, Sponsor: Chang Gung Memorial Hospital
Trial primary completion date: Jul 2016 --> Dec 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- Trial primary completion date: Imaging the Neural Network Connectivity on Patients With Mild Cognitive Impairment (clinicaltrials.gov) - Aug 9, 2016
P=N/A, N=108, Recruiting, Sponsor: Chang Gung Memorial Hospital
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Jul 2015 --> Aug 2016
- Trial primary completion date: REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN) (clinicaltrials.gov) - Aug 9, 2016
P=N/A, N=50, Recruiting, Sponsor: European Huntington's Disease Network
Trial primary completion date: Jul 2015 --> Aug 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- Trial primary completion date: REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) (clinicaltrials.gov) - Aug 9, 2016
P=N/A, N=10000, Recruiting, Sponsor: European Huntington's Disease Network
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- Byetta (exenatide) / AstraZeneca
Trial primary completion date: A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease (clinicaltrials.gov) - Aug 9, 2016
P2, N=100, Recruiting, Sponsor: National Institute on Aging (NIA)
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- Trial completion, Enrollment change: Delirium, Electroencephalographic Alterations and Cortical Spreading Depression (CSD) in Critical Illness (clinicaltrials.gov) - Aug 4, 2016
P=N/A, N=102, Completed, Sponsor: Glostrup University Hospital, Copenhagen
Trial primary completion date: Jul 2016 --> Jul 2017 Recruiting --> Completed | N=260 --> 102
- ||| Nuplazid (pimavanserin) / Acadia Pharma
Enrollment closed, Trial primary completion date: A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (clinicaltrials.gov) - Aug 3, 2016
P2, N=181, Active, not recruiting, Sponsor: ACADIA Pharmaceuticals Inc.
Recruiting --> Completed | N=260 --> 102 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016
- lorazepam / Generic mfg.
Enrollment closed, Enrollment change: The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms (clinicaltrials.gov) - Aug 1, 2016
P1, N=57, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016 Recruiting --> Active, not recruiting | N=75 --> 57
- Trial completion, Enrollment change, Trial primary completion date: Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=10, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=75 --> 57 Enrolling by invitation --> Completed | N=16 --> 10 | Trial primary completion date: Dec 2016 --> Jul 2016
- | donepezil / Generic mfg.
Trial completion: Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318) (clinicaltrials.gov) - Jul 26, 2016
P2, N=36, Completed, Sponsor: Merck Sharp & Dohme Corp.
Enrolling by invitation --> Completed | N=16 --> 10 | Trial primary completion date: Dec 2016 --> Jul 2016 Active, not recruiting --> Completed
- Trial completion, Enrollment change: MEDCED: Continuing Education in Nursing Home Dementia Care (clinicaltrials.gov) - Jul 25, 2016
P=N/A, N=274, Completed, Sponsor: Bergen University College
Active, not recruiting --> Completed Recruiting --> Completed | N=220 --> 274
- Trial primary completion date: A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment (clinicaltrials.gov) - Jul 24, 2016
P=N/A, N=100, Recruiting, Sponsor: Palo Alto Veterans Institute for Research
Recruiting --> Completed | N=220 --> 274 Trial primary completion date: Jan 2016 --> Sep 2016
- | Trial completion: Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training (clinicaltrials.gov) - Jul 23, 2016
P4, N=20, Completed, Sponsor: New York University School of Medicine
Trial primary completion date: Jan 2016 --> Sep 2016 Active, not recruiting --> Completed